Pre-Mkt News ->Pressure Biosciences, Inc. $PBIO Benefits From Surge In Life Sciences and Medical Technology Markets
http://finance.yahoo.com/news/pressure-biosci...00106.html
SALT LAKE CITY, UT / ACCESSWIRE / September 29, 2014 / Pressure Biosciences (PBIO) is a company at forefront of new technologies in the life sciences market. PBIO builds machines that use a special, high-pressure technology, something they call PCT (Pressure Cycling Technology). These machines use pressure to break apart larger tissue samples and extract molecules - think of a sand sifter breaking apart a larger piece of earth into much finer sand particles to extract what’s inside. PBIO’s machines do just that with molecules, and are sold to laboratories that prepare samples which are then used in such areas as forensics research, drug design, and biomarker discovery, depending on the laboratory or clinic.
PBIO, which is trading at .31 cents per share and maintains an average volume of 43K, has clearly received a boost from the booming biotech market. As biotech companies grow in relevance, raising a staggering 6.4 billion in investor capital last year, the interdependence of the medical industry continues to reveal itself. Tertiary markets like life sciences sprout new companies, products, and technologies, just like PBIO’s pressure technology machines, that are borne out of the necessity of supporting pharmaceuticals and biotechs, however, many of these smaller companies have emerged to make a name for themselves.
Before a complex new biologic drug arrives on the market for one of the biotechs, medical technicians will require the tools to develop it and test its readiness for consumers, which is where PBIO comes in. The company retains the experience of numerous years in the industry, but hit its stride in the last year and a half with the widespread development and marketing of its PCT technologies.
Overall revenue was up 9% between Q1 2013 and the same time frame in 2014, while product and service revenue climbed an impressive 82% as the company began to sell to laboratories at a more diligent pace. Consumables revenue grew by an astounding 101% while operating costs were almost identical to 2013’s figures, which is always a good sign. A recent announcement regarding the shipment and purchase of its latest PCT-based instrument system, Barozyme HT48, is a strong indicator that revenues will again be on the rise in the fourth quarter of 2014.
In addition to fostering products that make its brand synonymous with ingenuity and quality, Pressure Biosciences also happens to be benefiting from the upward swing of a few peripheral companies. Thermal Fisher Scientific (TMO), trading at 121.36 with a 48.47B market cap, is an industry giant predicted by The Wall Street Journal to increase in value by 20% over the next year. With an estimated 2014 revenue of nearly $17 billion and over 20 major acquisitions under its belt in the last five years, TMO serves as a pulse check for the financial status of the entire life sciences market, and its numbers represent the increased livelihood of this set of companies.
Another prime example of a robust company in this field is Medtronic (MDT), which recently received a boost from its Reveal LINQ device, an unimaginably small heart monitor used to measure electrical activity and can be inserted without surgery. The market for insertable devices designed this small is expected to grow to a half billion dollars by the turn of the decade, as once again, a medical necessity warrants the technology. Medtronic currently trades at 63.34 after a recent minor surge, and with the Reveal LINQ reportedly becoming Medtronic’s hottest device, the potential for sustained growth is more than apparent.
Enteromedics Inc. (ETRM), trading at 1.13 with a market cap of roughly 78M, also demonstrates promise in the field of insertable devices, as the company continues to make strides with its VBLOC therapy, a pacemaker-like apparatus that blocks a nerve in the digestive system that controls hunger, thereby acting as a remedy for obesity and metabolic diseases while also improving diabetes control.
ETRM and especially PBIO act as entryways into a life sciences industry marked by medical technologies that combat diseases and serve as necessary research tools. PBIO’s devices accomplish sample preparation for labs developing new drugs and researching evidence in rape crimes. All of the positive financial growth reflects the quality of Pressure Bioscience’s technologies and the willingness of its clients to invest in PCT technology. With PBIO’s market data and overall performance headed in the right direction, the level of confidence demonstrated by PBIO’s clients should also extend to investors pursuing the Company as a life sciences stock poised for future success.
Please visit PBIO on Facebook and Twitter
Pressure BioSciences, Inc. (PBI) (PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (?PCT?). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
http://finance.yahoo.com/news/pressure-biosci...00106.html
SALT LAKE CITY, UT / ACCESSWIRE / September 29, 2014 / Pressure Biosciences (PBIO) is a company at forefront of new technologies in the life sciences market. PBIO builds machines that use a special, high-pressure technology, something they call PCT (Pressure Cycling Technology). These machines use pressure to break apart larger tissue samples and extract molecules - think of a sand sifter breaking apart a larger piece of earth into much finer sand particles to extract what’s inside. PBIO’s machines do just that with molecules, and are sold to laboratories that prepare samples which are then used in such areas as forensics research, drug design, and biomarker discovery, depending on the laboratory or clinic.
PBIO, which is trading at .31 cents per share and maintains an average volume of 43K, has clearly received a boost from the booming biotech market. As biotech companies grow in relevance, raising a staggering 6.4 billion in investor capital last year, the interdependence of the medical industry continues to reveal itself. Tertiary markets like life sciences sprout new companies, products, and technologies, just like PBIO’s pressure technology machines, that are borne out of the necessity of supporting pharmaceuticals and biotechs, however, many of these smaller companies have emerged to make a name for themselves.
Before a complex new biologic drug arrives on the market for one of the biotechs, medical technicians will require the tools to develop it and test its readiness for consumers, which is where PBIO comes in. The company retains the experience of numerous years in the industry, but hit its stride in the last year and a half with the widespread development and marketing of its PCT technologies.
Overall revenue was up 9% between Q1 2013 and the same time frame in 2014, while product and service revenue climbed an impressive 82% as the company began to sell to laboratories at a more diligent pace. Consumables revenue grew by an astounding 101% while operating costs were almost identical to 2013’s figures, which is always a good sign. A recent announcement regarding the shipment and purchase of its latest PCT-based instrument system, Barozyme HT48, is a strong indicator that revenues will again be on the rise in the fourth quarter of 2014.
In addition to fostering products that make its brand synonymous with ingenuity and quality, Pressure Biosciences also happens to be benefiting from the upward swing of a few peripheral companies. Thermal Fisher Scientific (TMO), trading at 121.36 with a 48.47B market cap, is an industry giant predicted by The Wall Street Journal to increase in value by 20% over the next year. With an estimated 2014 revenue of nearly $17 billion and over 20 major acquisitions under its belt in the last five years, TMO serves as a pulse check for the financial status of the entire life sciences market, and its numbers represent the increased livelihood of this set of companies.
Another prime example of a robust company in this field is Medtronic (MDT), which recently received a boost from its Reveal LINQ device, an unimaginably small heart monitor used to measure electrical activity and can be inserted without surgery. The market for insertable devices designed this small is expected to grow to a half billion dollars by the turn of the decade, as once again, a medical necessity warrants the technology. Medtronic currently trades at 63.34 after a recent minor surge, and with the Reveal LINQ reportedly becoming Medtronic’s hottest device, the potential for sustained growth is more than apparent.
Enteromedics Inc. (ETRM), trading at 1.13 with a market cap of roughly 78M, also demonstrates promise in the field of insertable devices, as the company continues to make strides with its VBLOC therapy, a pacemaker-like apparatus that blocks a nerve in the digestive system that controls hunger, thereby acting as a remedy for obesity and metabolic diseases while also improving diabetes control.
ETRM and especially PBIO act as entryways into a life sciences industry marked by medical technologies that combat diseases and serve as necessary research tools. PBIO’s devices accomplish sample preparation for labs developing new drugs and researching evidence in rape crimes. All of the positive financial growth reflects the quality of Pressure Bioscience’s technologies and the willingness of its clients to invest in PCT technology. With PBIO’s market data and overall performance headed in the right direction, the level of confidence demonstrated by PBIO’s clients should also extend to investors pursuing the Company as a life sciences stock poised for future success.
Please visit PBIO on Facebook and Twitter
Pressure BioSciences, Inc. (PBI) (PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (?PCT?). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
